Clinical trials: Psilocybin
Depression, Parkinson's Disease (PD)
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
- Trial name
- PSI-PD (NCT07610369)
- Testing
- Psilocybin (drug)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yale University
Depressive Disorder, Major
Psilocybin for Major Depressive Disorder (MDD)
Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled.
- Trial name
- uAspire (NCT06308653)
- Testing
- Psilocybin 25 mg, Psilocybin 5 mg, Psychosocial Support
- Where
- 29 sites in United States
- Volunteers
- 238 people
- Sponsor
- Usona Institute
Depression, Burnout, Professional
PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout
This project is an open-label randomized study looking at an 8-week Mindfulness-Based Stress Reduction (MBSR) curriculum vs. an 8-week MBSR curriculum + a group psilocybin-assisted psychotherapy intervention for frontline…
- Trial name
- PAPR (NCT05557643)
- Testing
- Psilocybin, Mindfulness-Based Stress Reduction (MBSR)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Utah
Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD
The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training
The study investigates two groups of participants of the SÄPT therapist's training starting in October 2022. The overall objective is to investigate the risks and benefits of personal experience (PE) with substance-induced…
- Trial name
- TherPsySE (NCT05570708)
- Testing
- MDMA, LSD, psilocybin
- Where
- Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Felix Mueller
Healthy
Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects
The acute subjective effects of serotonin (5-HT)2A receptor stimulation with psilocybin in humans are mostly positive. However, negative effects such as anxiety, paranoid thinking, or loss of trust towards other people are common…
- Trial name
- MDMA-Psilo (NCT06884514)
- Testing
- Psilocybin, 3,4-Methylenedioxymethamphetamine
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Healthy
UW Psilocybin Pharmacokinetics Study
Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
- Trial name
- NCT02163707
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Major Depression
Study of Psilocybin Under Anesthesia Controlled by EEG
Major depressive disorder (MDD) affects millions of Americans and remains difficult to treat. Psilocybin, a psychedelic compound, has shown promise for reducing depression symptoms, but a key challenge in psychedelic research is…
- Trial name
- SPACE (NCT07479550)
- Testing
- Psilocybin (Usona Institute), Propofol
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Depressive Disorder, Major
Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept
Effects of serotonin 2A/1A receptor stimulation by psilocybin on mood and emotion processing in major depressive disorder: a randomized double-blind placebo-controlled study
- Trial name
- NCT03715127
- Testing
- Psilocybine oral capsule
- Where
- Switzerland
- Volunteers
- 55 people
- Sponsor
- University of Zurich
Aging
Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults
Participants in this study will undergo a series of non-invasive tests and activities designed to understand how a single dose of psilocybin might influence cognition and emotional well-being in healthy older adults.
- Trial name
- NCT06367738
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Anorexia Nervosa
Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa
The goal of this clinical trial is to learn if psilocybin, given with psychological support, is safe and helps treat anorexia nervosa in young adults.
- Trial name
- psiAN (NCT07169747)
- Testing
- Psilocybin
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Region Skane
Major Depressive Disorder
Psilocybin-assisted CBT for Depression
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2)…
- Trial name
- NCT05227612
- Testing
- Psilocybin, Cognitive behavioral therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Los Angeles
Severe Depression
Psilocybin and Depression
The main aim of the study is to investigate the possible long-term therapeutic effects of psilocybin on the symptoms of severe depression, as well as the brain mechanisms underlying these changes.
- Trial name
- Psilo101 (NCT03380442)
- Testing
- Psilocybin, Ketamine (Ketalar)
- Volunteers
- 60 people
- Sponsor
- University of Helsinki
Psilocybin
Precision Functional Brain Mapping in Psilocybin
This project will employ functional brain imaging to study the mechanism and immediate and long-term effects of psilocybin, a serotonin receptor 2A agonist, on cortical and cortico-subcortical brain networks in healthy adults.
- Trial name
- Psilocybin PFM (NCT04501653)
- Testing
- Psilocybin, Methylphenidate
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Depressive Disorder, Treatment-Resistant
Psilocybin-assisted Interpersonal Therapy for Depression
This is a single-arm, open-label interventional study of psilocybin-assisted interpersonal therapy for treatment resistant depression.
- Trial name
- NCT05581797
- Testing
- Psilocybin-assisted psychotherapy
- Where
- New Zealand
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Otago
Healthy
Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators
This is a double-blind placebo-controlled study investigating the acute and persisting effects of psilocybin on meditation, spirituality, health, well-being, prosocial attitudes, and brain functioning.
- Trial name
- NCT02145091
- Testing
- Moderately-high dose of psilocybin, Moderately-low dose of psilocybin, Very-low dose of psilocybin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Cancer
Psilocybin Cancer Anxiety Study
The primary objective of this double-blind, placebo-controlled pilot study is to assess the efficacy of psilocybin administration (4-phosphoryloxy-N,N-dimethyltryptamine), a serotonergic psychoactive agent, on psychosocial…
- Trial name
- NCT00957359
- Testing
- Psilocybin, Niacin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- NYU Langone Health